Path ID: DB00810_MESH_D010301_1
Concepts
| Identifier | Name | Type |
|---|---|---|
| MESH:D001712 | biperiden | Drug |
| UniProt:P11229 | Muscarinic acetylcholine receptor M1 | Protein |
| GO:0007271 | synaptic transmission, cholinergic | BiologicalProcess |
| HP:0100022 | Abnormality of movement | PhenotypicFeature |
| HP:0001300 | Parkinsonism | PhenotypicFeature |
| MESH:D010301 | Parkinson Disease, Postencephalitic | Disease |
Relationships
NOTE: predicates are annotated in Biolink Model (v1.3.0)
| Subject | Predicate | Object |
|---|---|---|
| Biperiden | NEGATIVELY REGULATES | Muscarinic Acetylcholine Receptor M1 |
| Muscarinic Acetylcholine Receptor M1 | POSITIVELY REGULATES | Synaptic Transmission, Cholinergic |
| Synaptic Transmission, Cholinergic | POSITIVELY CORRELATED WITH | Abnormality Of Movement |
| Abnormality Of Movement | POSITIVELY CORRELATED WITH | Parkinsonism |
| Parkinsonism | MANIFESTATION OF | Parkinson Disease, Postencephalitic |
Comment: The disease is denoted as Postencephalitic parkinsonism in the original file. This disease is believed to be caused by a viral infection, leading to clinical parkinsonism (https://en.wikipedia.org/wiki/Postencephalitic_parkinsonism) and anti-Parkinson drugs may be helpful in treating the symptoms (https://en.wikipedia.org/wiki/Encephalitis_lethargica). For example, muscarinic antagonists can allow dopamine levels to rebalance, which can help relieve some Parkinsonian symptoms e.g. involuntary movements. Anticholinergic drugs may also be prescribed to improve bladder dysfunction (https://pubmed.ncbi.nlm.nih.gov/20370804/).
Reference: